Grade ≥ 3 TEAE attributed to VEGFR TKI class effects in all patients and patients with prior CPI exposure.
| TEAE . | Tivozanib . | Sorafenib . | ||
|---|---|---|---|---|
| ITT N = 173, (%) . | Prior-CPI N = 47, (%) . | ITT N = 170, (%) . | Prior-CPI N = 44, (%) . | |
| All TEAE | 80 (46) | 27 (58) | 94 (55) | 29 (67) |
| HTN | 35 (20) | 16 (35) | 23 (14) | 5 (12) |
| Diarrhea | 3 (2) | 1 (2) | 16 (9) | 2 (5) |
| Asthenia | 8 (5) | 1 (2) | 6 (4) | 3 (7) |
| Nausea/Vomiting | 0 | 0 | 4 (2) | 1 (2) |
| Rash | 0 | 0 | 13 (8) | 10 (23) |
| PPE | 1 (1) | 0 | 17 (10) | 5 (12) |
| TEAE . | Tivozanib . | Sorafenib . | ||
|---|---|---|---|---|
| ITT N = 173, (%) . | Prior-CPI N = 47, (%) . | ITT N = 170, (%) . | Prior-CPI N = 44, (%) . | |
| All TEAE | 80 (46) | 27 (58) | 94 (55) | 29 (67) |
| HTN | 35 (20) | 16 (35) | 23 (14) | 5 (12) |
| Diarrhea | 3 (2) | 1 (2) | 16 (9) | 2 (5) |
| Asthenia | 8 (5) | 1 (2) | 6 (4) | 3 (7) |
| Nausea/Vomiting | 0 | 0 | 4 (2) | 1 (2) |
| Rash | 0 | 0 | 13 (8) | 10 (23) |
| PPE | 1 (1) | 0 | 17 (10) | 5 (12) |
Abbreviations: TEAE, Treatment emergent adverse event; ITT, intention to treat; CPI, checkpoint inhibitor; HTN, hypertension; PPE, palmo-plantar dysesthesia.
Grade ≥ 3 TEAE attributed to VEGFR TKI class effects in all patients and patients with prior CPI exposure.
| TEAE . | Tivozanib . | Sorafenib . | ||
|---|---|---|---|---|
| ITT N = 173, (%) . | Prior-CPI N = 47, (%) . | ITT N = 170, (%) . | Prior-CPI N = 44, (%) . | |
| All TEAE | 80 (46) | 27 (58) | 94 (55) | 29 (67) |
| HTN | 35 (20) | 16 (35) | 23 (14) | 5 (12) |
| Diarrhea | 3 (2) | 1 (2) | 16 (9) | 2 (5) |
| Asthenia | 8 (5) | 1 (2) | 6 (4) | 3 (7) |
| Nausea/Vomiting | 0 | 0 | 4 (2) | 1 (2) |
| Rash | 0 | 0 | 13 (8) | 10 (23) |
| PPE | 1 (1) | 0 | 17 (10) | 5 (12) |
| TEAE . | Tivozanib . | Sorafenib . | ||
|---|---|---|---|---|
| ITT N = 173, (%) . | Prior-CPI N = 47, (%) . | ITT N = 170, (%) . | Prior-CPI N = 44, (%) . | |
| All TEAE | 80 (46) | 27 (58) | 94 (55) | 29 (67) |
| HTN | 35 (20) | 16 (35) | 23 (14) | 5 (12) |
| Diarrhea | 3 (2) | 1 (2) | 16 (9) | 2 (5) |
| Asthenia | 8 (5) | 1 (2) | 6 (4) | 3 (7) |
| Nausea/Vomiting | 0 | 0 | 4 (2) | 1 (2) |
| Rash | 0 | 0 | 13 (8) | 10 (23) |
| PPE | 1 (1) | 0 | 17 (10) | 5 (12) |
Abbreviations: TEAE, Treatment emergent adverse event; ITT, intention to treat; CPI, checkpoint inhibitor; HTN, hypertension; PPE, palmo-plantar dysesthesia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
